Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drug-drug Interaction Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Subjects With Castration-Resistant Prostate Cancer

Trial Profile

Drug-drug Interaction Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Subjects With Castration-Resistant Prostate Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apalutamide (Primary) ; Fexofenadine; Midazolam; Omeprazole; Pioglitazone; Rosuvastatin; Vitamin K; Warfarin
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Aragon Pharmaceuticals

Most Recent Events

  • 05 Dec 2024 Planned End Date changed from 1 Dec 2027 to 31 Dec 2027.
  • 09 Oct 2024 Planned End Date changed from 31 Dec 2024 to 1 Dec 2027.
  • 17 Jul 2024 Planned End Date changed from 1 Dec 2024 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top